Osaic Holdings Inc. Boosts Holdings in Cigna Group $CI

Osaic Holdings Inc. increased its position in Cigna Group (NYSE:CI) by 38.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,442 shares of the health services provider’s stock after purchasing an additional 14,437 shares during the period. Osaic Holdings Inc.’s holdings in Cigna Group were worth $17,323,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of CI. Price T Rowe Associates Inc. MD lifted its stake in shares of Cigna Group by 10.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,056,806 shares of the health services provider’s stock worth $3,966,690,000 after buying an additional 1,094,327 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Cigna Group by 1.1% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 11,778,472 shares of the health services provider’s stock worth $3,893,727,000 after acquiring an additional 123,479 shares during the last quarter. Dodge & Cox raised its holdings in Cigna Group by 0.7% in the 2nd quarter. Dodge & Cox now owns 8,950,610 shares of the health services provider’s stock worth $2,958,893,000 after acquiring an additional 60,877 shares during the last quarter. Valeo Financial Advisors LLC lifted its position in Cigna Group by 86,071.1% in the 2nd quarter. Valeo Financial Advisors LLC now owns 3,475,282 shares of the health services provider’s stock valued at $1,148,859,000 after acquiring an additional 3,471,249 shares in the last quarter. Finally, Norges Bank purchased a new stake in Cigna Group during the 2nd quarter valued at $1,110,426,000. 86.99% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO David Cordani acquired 4,134 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were purchased at an average price of $241.88 per share, with a total value of $999,931.92. Following the completion of the purchase, the chief executive officer directly owned 157,935 shares of the company’s stock, valued at $38,201,317.80. This represents a 2.69% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brian C. Evanko sold 5,368 shares of Cigna Group stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $300.00, for a total value of $1,610,400.00. Following the transaction, the insider directly owned 51,182 shares in the company, valued at approximately $15,354,600. The trade was a 9.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on CI. The Goldman Sachs Group decreased their price target on Cigna Group from $370.00 to $330.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Jefferies Financial Group reissued a “buy” rating and issued a $310.00 target price on shares of Cigna Group in a research report on Monday, November 3rd. Barclays dropped their price target on shares of Cigna Group from $383.00 to $300.00 and set an “overweight” rating on the stock in a report on Friday, October 31st. Sanford C. Bernstein reduced their price target on shares of Cigna Group from $346.00 to $294.00 and set a “market perform” rating for the company in a research note on Wednesday, November 12th. Finally, TD Cowen lowered their price objective on shares of Cigna Group from $387.00 to $333.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $331.83.

Cigna Group Trading Up 0.0%

Cigna Group stock opened at $273.87 on Friday. Cigna Group has a 52-week low of $239.51 and a 52-week high of $350.00. The company has a market cap of $73.16 billion, a P/E ratio of 12.08, a P/E/G ratio of 0.99 and a beta of 0.26. The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of 0.74. The business has a 50-day simple moving average of $277.98 and a two-hundred day simple moving average of $293.10.

Cigna Group (NYSE:CI) last posted its quarterly earnings data on Thursday, October 30th. The health services provider reported $7.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.64 by $0.19. The company had revenue of $69.57 billion for the quarter, compared to the consensus estimate of $66.40 billion. Cigna Group had a net margin of 2.29% and a return on equity of 18.80%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm posted $7.51 earnings per share. Cigna Group has set its FY 2025 guidance at 29.600- EPS. Analysts predict that Cigna Group will post 29.77 EPS for the current year.

Cigna Group Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Thursday, December 4th were paid a $1.51 dividend. This represents a $6.04 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Thursday, December 4th. Cigna Group’s dividend payout ratio is 26.64%.

Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.